Phase 2 N=180 EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
Prostate Cancer Metastatic
Primary: Progression Free Survival (PFS) Time — 3.3; 3.4; 4.3 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Primary: Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR]) — 6.8 percentage of participants
Phase 2 N=119 A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostate Cancer
Primary: Percentage of Participants With Total Serum PSA Response — 29; 32; 11; 21 % of responders
Phase 3 N=1,028 Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Prostate Cancer · Castration Resistant Prostate Cancer · Pain
Primary: Overall Survival (OS) — 11.0; 9.8 months — p=0.213
Phase 3 N=1,195 Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Prostatic Neoplasms
Primary: Overall Survival — 450.0; 332.0 Days — p=<0.0001
Phase 2 N=7 Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Stage IVB Prostate Cancer AJCC v8
Primary: Overall Response Rate (ORR) — 50 percentage of participants
N/A N=20 Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline
Phase 2 N=63 Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Prostate Cancer Metastatic
Primary: Percentage of Participants With PSA Response — 39.7; 15.9; 55.6 percentage of participants
Phase 2 N=9 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Metastatic Castration-resistant Prostate Cancer
Primary: Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies — 5; 0; 3; 0 Participants
Phase 2 N=17 A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Prostate Cancer
Primary: Clinical Benefit Rate From Cabozantinib (XL184) — 10 Participants
Phase 1 N=27 A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
Prostate Cancer · Hormone Refractory Prostate Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 0; 6; 14; 8 Participants
Phase 2 N=10 Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Prostate Cancer
Primary: Phase 1: Maximally Tolerated Dose (MTD) of Cabazitaxel in Combination With Abiraterone Acetate — 25 mg/m^2
Phase 2 N=21 A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
Prostate Cancer · Metastatic Castrate Resistant Prostate Cancer
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 Given Every Two Weeks. — 20 mg/kg every 2 weeks
Phase 2 N=61 CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) or Radiographic Progression — 10 participants
Phase 1 N=6 Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Prostatic Neoplasms · Prostatic Cancer
Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0 Participants
Phase 3 N=1,168 Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Prostate Cancer
Primary: Overall Survival (OS) — 24.3; 24.5; 25.2 months — p=0.7574
Phase 2 N=9 Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
Metastatic Castration-Resistant Prostate Cancer
Primary: Median Time on Treatment — 11 weeks
Phase 3 N=1,088 Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 34.66; 30.29 Months
Phase 2 N=8 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Participants With PSA50 Response — 2 Participants
Phase 2 N=26 Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Castration Resistant Prostatic Cancer · Metastatic Prostate Cancer
Primary: Radiographic Progression-Free Survival Rate (rPFS) at 6 Months — 0.513; 0.63 proportion of participants
Phase 2 N=26 Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Metastatic Malignant Neoplasm in the Bone · Prostate Adenocarcinoma
Primary: Number of Adverse Events — 236; 14 adverse events
Phase 2 N=170 Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Lymphadenopathy
Primary: Maximum Tolerated Dosage (MTD) of Cabazitaxel-carboplatin in the Phase I Portion of Study — 25 mg/m^2
Phase 2 N=67 Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Primary: Number of Patients With Gene Alterations — 7; 4; 7; 7 Participants
Phase 2 N=14 Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: Proportion of Patients With PSA Decline by 50% From Baseline — 9; 5 Participants
Phase 2 N=28 Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
Metastatic Castration-resistant Prostate Cancer
Primary: Progression-free Survival (PFS) — 1 Participants
Phase 1 N=17 A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
Prostate Cancer
Primary: Frequency of Dose-limiting Toxicity at Escalating Dose Levels of CTT1403 — 0; 0; 0; 0 Participants
Phase 4 N=255 Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
Prostate Cancer Metastatic
Primary: Radiographic Progression-Free Survival (rPFS) — 8.0; 3.7 months — p=<0.0001
N/A N=25 Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
Prostate Cancer
Primary: Overall Survival (Favorable and Unfavorable ) — 13.9; 36.3 months
Phase 2 N=41 Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
Prostate Cancer
Primary: Metabolic Syndrome — 0; 0 kilograms
Phase 2 N=13 ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: PSA Decline of >= 50% (PSA50) From Baseline — 7.7 percentage of participants